Gilead Sciences is granting licenses to six companies to produce lenacapavir for pre-exposure prophylaxis, as well as for ...

The collaboration supports efforts for HIV prevention through PrEP, emphasizing Hetero’s commitment to improving HIV care.

Gilead signs non-exclusive, royalty-free voluntary licensing agreements with six generic companies to market its ...

Fewer young people are having sex, but the teens and young adults who are sexually active aren't using condoms as regularly, ...

Condom usage is down for everyone in the U.S., but researchers say the trend is especially stark among teens and young adults ...

HIV expert Linda-Gail Bekker talks to The Conversation Weekly about promising results from a trial of a new drug for HIV ...

How supplies of GLP-1 drugs could be at risk as a result of the dockworker strike occurring across the East and Gulf coasts: ...

Indian pharmaceutical companies are set to produce generic versions of lenacapavir, an HIV prevention drug, under agreements ...

Lenacapavir was approved for use in HIV-positive adults with multi-drug resistance by the European Union in August 2022 and ...

Six drugmakers sign agreements with Gilead Sciences to produce generic lenacapavir, a long-acting HIV drug, amid patent ...

Gilead Sciences signs voluntary licensing agreement with six pharma firms to produce generic lenacapavir: Our Bureau, New Delhi Thursday, October 3, 2024, 11:30 Hrs [IST] US-based ...

Gilead Sciences, Inc. has announced that it has signed non-exclusive, royalty-free voluntary licensing agreements with six ...